Published in Pharma Law Weekly, January 11th, 2005
To date, clinical investigations have been supported by grants from the U.S. National Institutes of Health, including the Rapid Access to Investigational Drugs program. A request for designation of LR3001 as an orphan drug for the treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly